Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

193

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

April 27, 2022

Study Completion Date

April 27, 2022

Conditions
Advanced Cancer
Interventions
DRUG

MGCD516

MGCD516 is a small molecule inhibitor of several closely related receptor tyrosine kinases. MGCD516 capsules will be taken with water.

Trial Locations (43)

10032

Columbia University, New York

10467

Montefiore Medical Center, The Bronx

14263

Roswell Park Cancer Institute, Buffalo

18840

Guthrie Clinical Research, Sayre

20850

Maryland Oncology Hematology,, Rockville

22031

Virginia Cancer Specialists, Fairfax

24014

Oncology and Hematology Associates of Southwest Virginia, Inc., Blue Ridge Cancer Care, Roanoke

29607

St. Francis Cancer Center, Greenville

33308

Holy Cross Michael & Dianne Bienes Comprehensive Cancer Center, Fort Lauderdale

34232

Florida Cancer Specialists, Sarasota

34471

Florida Cancer Affiliates, Ocala

35294

University of Alabama, Birmingham

37203

Sarah Cannon Research Institute, Nashville

45242

Oncology Hematology Care, Inc., Cincinnati

48109

University of Michigan, Ann Arbor

48202

Henry Ford Health System, Detroit

53792

University of Wisconsin, Madison

60611

Northwestern University, Chicago

60612

Rush University Medical Center, Chicago

63110

Washington University Center for Advanced Medicine, St Louis

68130

Oncology Hematology West PC, Nebraska Cancer Specialists, Omaha

68803

CHI Health St Francis, Saint Francis Cancer Treatment Center, Grand Island

70121

Ochsner Clinic Foundation, New Orleans

75251

Mary Crowley Cancer Research Center, Dallas

75702

Texas Oncology-Tyler, Tyler

77030

University of Texas, MD Anderson Cancer Center, Houston

78705

Texas Oncology-Austin Midtown, Austin

80218

Rocky Mountain Cancer Center, Denver

84112

The Huntsman Cancer Institute, Salt Lake City

87102

University of New Mexico Cancer Research and Treatment Center, Albuquerque

90403

Sarcoma Oncology Research Center, Santa Monica

90602

Innovative Clinical Research Institute, Whittier

92093

University of California, San Diego, San Diego

94143

University of California, San Francisco, San Francisco

98109

Seattle Cancer Care Alliance, Seattle

98684

Northwest Cancer Specialists, P.C., Vancouver

02114

Massachusetts General Hospital, Boston

Unknown

Chungbuk National University Hospital, Cheongju-si

Keimyung University Dongsan Hospital, Daegu

National Cancer Center, Goyang-si

Korea Veterans Health Service, Seoul

Seoul National University Hospital, Seoul

Severance Hospital, Yonsei University Health System, Seoul

Sponsors
All Listed Sponsors
lead

Mirati Therapeutics Inc.

INDUSTRY

NCT02219711 - Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer | Biotech Hunter | Biotech Hunter